CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how effective lower doses of CPX-351 are in older
participants with relapsed/refractory acute myeloid leukemia (AML) who are not eligible to
receive intensive chemotherapy and in participants with myelodysplastic syndromes (MDS) after
Hypomethylating Agents (HMA) failure.